• CytoDyn posted a net loss of $42.7 million, swinging from net income of $3.7 million a year earlier.
• Operating loss widened to $38.6 million as operating expenses climbed to $38.6 million, reflecting a $15.4 million legal settlement loss.
• Research and development expense rose 193% to $15.7 million, driven by higher clinical costs tied to the Phase 2 colorectal cancer CLOVER study.
• Cash and cash equivalents ended at $11.9 million, little changed from a year earlier, while net cash used in operations increased to $17.3 million.
• Enrollment in the CLOVER Phase 2 trial topped 60 patients; a Natera collaboration will add ctDNA-guided analyses to trial samples and real-world data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001175680-26-000014), on August 31, 2026, and is solely responsible for the information contained therein.